Redeye reiterates its positive stance following Physitrack’s Q1 results. The reported figures met our expectations, with q/q growth returning. The overall outlook is optimistic, and Q2 seems to be off to a solid start. Our view is that the case remains intact, and so is our valuation with a Base case of SEK35, with considerable upside potential in the share price emphasised.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Physitrack - Steady beginning to 2024

© Modular Finance, source Nordic Press Releases